Rhumbline Advisers Reduces Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Rhumbline Advisers lowered its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 6.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,460 shares of the biotechnology company’s stock after selling 108 shares during the quarter. Rhumbline Advisers’ holdings in Ascendis Pharma A/S were worth $201,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of ASND. Assetmark Inc. acquired a new stake in shares of Ascendis Pharma A/S during the third quarter worth about $331,000. Crossmark Global Holdings Inc. purchased a new position in Ascendis Pharma A/S in the third quarter valued at approximately $1,212,000. Oppenheimer Asset Management Inc. grew its position in shares of Ascendis Pharma A/S by 10.0% during the third quarter. Oppenheimer Asset Management Inc. now owns 7,622 shares of the biotechnology company’s stock worth $1,138,000 after acquiring an additional 695 shares during the last quarter. Sivik Global Healthcare LLC purchased a new position in shares of Ascendis Pharma A/S during the third quarter worth approximately $1,493,000. Finally, Thrivent Financial for Lutherans grew its position in shares of Ascendis Pharma A/S by 0.3% during the third quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company’s stock worth $11,717,000 after acquiring an additional 228 shares during the last quarter.

Ascendis Pharma A/S Stock Down 5.2 %

Shares of ASND opened at $138.18 on Tuesday. The business’s 50 day moving average is $137.36 and its two-hundred day moving average is $134.36. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $158.00. The firm has a market cap of $8.39 billion, a price-to-earnings ratio of -19.46 and a beta of 0.62.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. On average, equities analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Evercore ISI increased their price target on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday, February 18th. Oppenheimer reduced their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a report on Friday, November 15th. JPMorgan Chase & Co. raised their target price on Ascendis Pharma A/S from $167.00 to $168.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. The Goldman Sachs Group raised their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Finally, Wedbush reissued an “outperform” rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $202.36.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.